grant
A systems biology approach to identifying mechanisms underlying enhanced reactogenicity after mRNA-based vaccination
Organization LOUIS STOKES CLEVELAND VA MEDICAL CENTERLocation CLEVELAND, UNITED STATESPosted 1 Apr 2026Deadline 31 Mar 2030
VANIHUS FederalResearch GrantFY20262019-nCoV vaccineAcheActivities of Daily LivingActivities of everyday lifeAddressAdverse ExperienceAdverse eventAgeAntigensAssayAutomobile DrivingBioassayBioinformaticsBiologicalBiological AssayBlood SampleBlood SerumBlood specimenCOVID-19COVID-19 associated deathCOVID-19 associated fatalityCOVID-19 associated mortalityCOVID-19 deathCOVID-19 fatalityCOVID-19 induced deathCOVID-19 induced fatalityCOVID-19 induced mortalityCOVID-19 mortalityCOVID-19 related deathCOVID-19 related fatalityCOVID-19 related mortalityCOVID-19 vaccinationCOVID-19 vaccineCOVID19 associated deathCOVID19 associated fatalityCOVID19 associated mortalityCOVID19 deathCOVID19 fatalityCOVID19 induced deathCOVID19 induced fatalityCOVID19 induced mortalityCOVID19 mortalityCOVID19 related deathCOVID19 related fatalityCOVID19 related mortalityCV-19Cell BodyCell Mediated ImmunologyCell-Mediated ImmunityCellsCellular ImmunityCephalalgiaCephalgiaCephalodyniaCharacteristicsChemotactic CytokinesChillsClinicalCommunitiesCoronavirus Infectious Disease 2019Cranial PainData SetDevelopmentDiseaseDisorderDoseEducation for InterventionEducational InterventionEnrollmentEventExhibitsFDA EUAFDA Emergency Use AuthorizationFatigueFearFood and Drug Administration EUAFood and Drug Administration Emergency Use AuthorizationFrightGrippeHead PainHeadacheHealthHealth Care ProvidersHealth PersonnelHomologous Chemotactic CytokinesHourImmuneImmune Cell ActivationImmune responseImmunesImmunologic ModelImmunological ModelsIndividualInflammasomeInflammatoryInflammatory ResponseInfluenzaInfluenza VaccinesInjectionsInsectaInsectsInsects InvertebratesInstruction InterventionIntercrinesLack of EnergyLinkMessenger RNAMetabolicMetabolic PathwayMethodologyModelingModerna COVID-19 vaccineModerna coronavirus disease 2019 vaccineModificationMorbidityMuscleMuscle TissueMutateNational Institutes of HealthOlder PopulationOutcomePainPainfulParticipantPathway interactionsPatient EducationPatient InstructionPatient TrainingPatientsPersonsPhasePhase 3 Clinical TrialsPhase III Clinical TrialsPopulationPredispositionProductionProviderPublishingRNA immunizationRNA vaccinationRNA vaccineRNA-based vaccineRSV VaccinesReactionRecommendationReporterReportingResearch ResourcesResourcesRespiratory Syncytial Virus VaccinesRoleSARS-CoV-2 associated deathSARS-CoV-2 associated fatalitySARS-CoV-2 associated mortalitySARS-CoV-2 deathSARS-CoV-2 fatalitySARS-CoV-2 induced deathSARS-CoV-2 induced fatalitySARS-CoV-2 induced mortalitySARS-CoV-2 mortalitySARS-CoV-2 related deathSARS-CoV-2 related fatalitySARS-CoV-2 related mortalitySARS-CoV-2 vaccinationSARS-CoV-2 vaccineSARS-coronavirus-2 vaccineSIS cytokinesSerious Adverse EventSerologySerumSevere Acute Respiratory Syndrome CoV 2 vaccineSevere Adverse EventSevere acute respiratory syndrome coronavirus 2 vaccinationSevere acute respiratory syndrome coronavirus 2 vaccineSeveritiesSideSiteSpikevaxSusceptibilitySystems BiologyTechnologyTherapeuticTraining InterventionTranslationsTrustUnited States National Institutes of HealthVaccinationVaccinesVariantVariationVeteransWorkaccept vaccinationaccept vaccineage associated effectsage effectage related effectsagesaging effectbiologicchemoattractant cytokinechemokinecohortcoronavirus disease 2019coronavirus disease 2019 associated deathcoronavirus disease 2019 associated fatalitycoronavirus disease 2019 associated mortalitycoronavirus disease 2019 deathcoronavirus disease 2019 fatalitycoronavirus disease 2019 induced deathcoronavirus disease 2019 induced fatalitycoronavirus disease 2019 induced mortalitycoronavirus disease 2019 mortalitycoronavirus disease 2019 related deathcoronavirus disease 2019 related fatalitycoronavirus disease 2019 related mortalitycoronavirus disease 2019 vaccinationcoronavirus disease 2019 vaccinecoronavirus disease-19coronavirus disease-19 mortalitycoronavirus disease-19 vaccinecoronavirus infectious disease-19cytokinedaily living functiondaily living functionalitydeath due to COVID-19death due to COVID19death due to SARS-CoV-2death due to coronavirus disease 2019death due to severe acute respiratory syndrome coronavirus 2death in COVIDdeath in COVID-19death in SARS-CoV-2death in coronavirus diseasedeath in coronavirus disease 2019death in severe acute respiratory syndrome coronavirus 2develop a vaccinedevelop vaccinesdevelopment of a vaccinedevelopmentaldrivingeggemergency use authorizationenrollfatality due to COVID-19fatality due to COVID19fatality due to SARS-CoV-2fatality due to coronavirus disease 2019fatality due to severe acute respiratory syndrome coronavirus 2fluflu vaccineflu virus vaccinefunctional abilityfunctional capacityhead achehealth care personnelhealth care workerhealth providerhealth staffhealth workershealth workforcehealthcare employeeshealthcare staffhealthcare workforcehesitant to vaccinationhigh dimensionalityhost responseimmune activationimmune response to vaccinationimmune response to vaccinesimmune system responseimmunization side effectsimmunogenimmunogenicityimmunoresponseimpact of ageimprovedin vivoinfluence of ageinfluenza virus vaccineinnovateinnovationinnovativeinstructional interventionintervention designlife spanlifespanmRNAmRNA immunizationmRNA vaccinationmRNA vaccinemRNA-1273mRNA-based vaccinemRNA1273medical care providersmedical personnelmilitary veteranmortality due to COVID-19mortality due to COVID19mortality due to SARS-CoV-2mortality due to coronavirus disease 2019mortality due to severe acute respiratory syndrome coronavirus 2muscularnCoV vaccinenCoV-19 vaccinenCoV19 vaccineolder groupsolder individualsolder personopen labelopen label studyoutcome following vaccinationoutcome following vaccinepathogenpathwayphase III protocolpreservationpreventpreventingreaction to vaccinereactions to vaccinationresponseresult following vaccinationresult following vaccineserious adverse experienceserious adverse reactionsevere acute respiratory syndrome coronavirus 2 associated deathsevere acute respiratory syndrome coronavirus 2 associated fatalitysevere acute respiratory syndrome coronavirus 2 associated mortalitysevere acute respiratory syndrome coronavirus 2 deathsevere acute respiratory syndrome coronavirus 2 fatalitysevere acute respiratory syndrome coronavirus 2 induced deathsevere acute respiratory syndrome coronavirus 2 induced fatalitysevere acute respiratory syndrome coronavirus 2 induced mortalitysevere acute respiratory syndrome coronavirus 2 mortalitysevere acute respiratory syndrome coronavirus 2 related deathsevere acute respiratory syndrome coronavirus 2 related fatalitysevere acute respiratory syndrome coronavirus 2 related mortalitysexside effect following vaccineside effects associated with vaccinessocial rolestandard of caretherapeutic targettherapy designtranscriptomicstranslationtreatment designtreatment provideruptakevaccinate against COVID-19vaccinate against SARS-CoV-2vaccinate against coronavirus disease 2019vaccinate against severe acute respiratory syndrome coronavirus 2vaccination acceptabilityvaccination acceptancevaccination against COVID-19vaccination against SARS-CoV-2vaccination against Severe acute respiratory syndrome coronavirus 2vaccination against coronavirus disease 2019vaccination confidencevaccination hesitancyvaccination outcomevaccination resultvaccination side effectsvaccination uptakevaccination willingnessvaccine acceptabilityvaccine acceptancevaccine against 2019-nCovvaccine against COVID-19vaccine against SARS-CoV-2vaccine against SARS-coronavirus-2vaccine against Severe Acute Respiratory Syndrome CoV 2vaccine against Severe acute respiratory syndrome coronavirus 2vaccine against fluvaccine against influenzavaccine associated immune responsevaccine associated side effectvaccine candidates against SARS-CoV-2vaccine confidencevaccine developmentvaccine efficacyvaccine for novel coronavirusvaccine hesitancyvaccine hesitantvaccine immune responsevaccine immunogenicityvaccine induced immune responsevaccine induced side effectvaccine outcomevaccine platformvaccine reactionvaccine reactogenicityvaccine related side effectvaccine responsevaccine responsivenessvaccine resultvaccine side effectsvaccine uptakevaccine willingnessvaccine-induced responsevaccine-related reactionsvaccines preventing COVIDvaccines to prevent COVIDveteran population
Description preview
Project Summary Abstract
Significance to the VA: Vaccine hesitancy toward COVID-19 mRNA vaccines remains a significant
challenge. Identifying ways to reduce hesitancy is a key objective of these studies. Reactogenicity refers
to adverse events (AEs) that occur shortly after vaccination as a physical manifestation of the
inflammatory response.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click